RT @mmamas1973: @VictorDayan1 @LATAM_LACES @ACCinTouch @escardio @AHAScience Building new risk stratification tool makes more sense then re…
RT @mmamas1973: @VictorDayan1 @LATAM_LACES @ACCinTouch @escardio @AHAScience Building new risk stratification tool makes more sense then re…
@VictorDayan1 @LATAM_LACES @ACCinTouch @escardio @AHAScience Building new risk stratification tool makes more sense then re-calibrating existing ones. That's the approach we did in the United Kingdom for our TAVR risk score, following assessment of existin
15 / #230papers: Clinical prediction in defined populations: a simulation study investigating ... https://t.co/f9afrn7Kte #bmcmedresmethodol
RT @glen_martin1: When and how to utilise existing clinical prediction models in defined populations. https://t.co/67Yz0bInKC #bmcmedresmet…
RT @glen_martin1: When and how to utilise existing clinical prediction models in defined populations. https://t.co/67Yz0bInKC #bmcmedresmet…
RT @glen_martin1: When and how to utilise existing clinical prediction models in defined populations. https://t.co/67Yz0bInKC #bmcmedresmet…
RT @glen_martin1: When and how to utilise existing clinical prediction models in defined populations. https://t.co/67Yz0bInKC #bmcmedresmet…
RT @glen_martin1: When and how to utilise existing clinical prediction models in defined populations. https://t.co/67Yz0bInKC #bmcmedresmet…
RT @glen_martin1: When and how to utilise existing clinical prediction models in defined populations. https://t.co/67Yz0bInKC #bmcmedresmet…
RT @glen_martin1: When and how to utilise existing clinical prediction models in defined populations. https://t.co/67Yz0bInKC #bmcmedresmet…
When and how to utilise existing clinical prediction models in defined populations. https://t.co/67Yz0bInKC #bmcmedresmethodol @HeRC_Farr